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DOI: 10.1111/bcp.14089COMMENTARYBiosimilar and interchangeable: Inseparable scientific concepts?As defined by the European Commission, the term interchangeability
refers to “the possibility of exchanging one medicine for another that
is expected to have the same clinical effect.”1 In the context of
biosimilars the term interchangeability has caused confusion. Likely
due to specific regulatory requirements in the United States, physicians
sometimes interpret interchangeability as the potential for a biologic to
be substituted by a biosimilar at the pharmacy level, without the involve-
ment of a physician. However, interchangeability between a biological
reference medicine and a corresponding biosimilar medicine should
not be defined by its practical application; whether physician‐driven
switch or pharmacist‐driven substitution. Interchangeability, ie, the pos-
sibility of safely and effectively changing a reference medicine by its
biosimilar, or vice‐versa, in a given patient, should be rather recognized
as a scientific concept. In this paper, we review the evidence supporting
the assertion that interchangeability is inherent to biosimilarity.
In science, a conclusion is reached when a hypothesis is tested by
the use of an appropriate experimental approach. The aim of biosimilar
development is to replicate an existing biomedicine. Biosimilarity must
be substantiated by robust scientific evidence. To generate such evi-
dence, a hypothesis of high similarity between a biosimilar candidate
and the original reference medicine should be verified through well‐
established and validated methodologies that aim to identify all the
potential relevant physicochemical differences, but are also capable of
detecting even clinically meaningless differences. The acceptable dif-
ference level between the biosimilar candidate and the reference med-
icine is determined to a qreat extent by a thorough assessment of
multiple batches of the reference biologic. Indeed, no approved biolog-
ical medicine, whether original or not, is structurally identical to itself,
due to an intrinsic batch‐to‐batch variability that can be enhanced by
manufacturing changes. Although different batches of reference bio-
logical compounds are not identical to each other, they may be consid-
ered essentially equal and therapeutically indistinguishable. Therefore,
there is a clinically acceptable range of inherent structural heterogene-
ity for any biological product.2,3 As a consequence, many patients have
likely been treated with structurally slightly different versions of any
given reference biomedicine, which constitutes a de facto switch of
insignificant therapeutic concern. The approach used to substantiate
biosimilarity represents a refinement of the procedures that have been
securely applied for decades to batches of biologics that are subject to
manufacturing changes,4 but also to the very precise discrimination
between native and non‐native proteins during the monitoring of- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2460 wileyonlinelibrary.com/journal/bcpdoping in sports. Indeed, the differentiation between an endogenously
produced protein, such as erythropoietin, and an externally adminis-
tered version, such as epoetin alfa or beta, requires extremely sophisti-
cated laboratory techniques.5,6 The experience in analysing differences
among batches of original biological agents has shown that no clinical
comparison of efficacy and safety can match the accuracy and sensitiv-
ity of a stringent physicochemical and functional comparability. The rig-
orous regulation applied to the intrinsic variability of original biologics
has thus been extended to the pioneering guidance regarding
biosimilar‐to‐originator comparability put forth by the European Medi-
cines Agency (EMA).7 The magnitude of acceptable physicochemical
differences between biosimilars and their corresponding reference bio-
logics can confidently be assessed in the laboratory, where the differ-
ences in critical quality attributes must be shown not to exceed the
batch‐to‐batch variability of the reference biologic.
In addition to analytical comparability, biosimilarity is further sup-
ported by the demonstration of comparable pharmacokinetic, and pos-
sibly pharmacodynamic, clinical data.8 Furthermore, although clinicians
are primarily familiar with the traditional benefit‐to‐risk balance
assessment in patients for new medicines, the paradigm changes when
assessing comparability, rather than therapeutic benefit per se. Indeed,
when a biosimilar designation is to be granted, patient trials are con-
sidered to be confirmatory because of the superior value of analytical
studies for comparative purposes.9 Accordingly, the necessity of
patient trials has been a matter of debate for a number of years.10 In
light of current practical evidence, the issue is being raised again.11
In fact, the EMA already allows efficacy trials in patients to be waived
for insulin biosimilar candidates,12 and it introduced the possibility of
bypassing patient trials for filgrastim biosimilar candidates.13 The total-
ity of the evidence generated under a stringent regulatory framework,
such as EMA's, indicates that biosimilars and their reference medicines
essentially overlap structurally, thus clinically. Under these circum-
stances, if two versions of any given biologic were unable to be safely
interchanged, whether that refers to two batches of any given biologic
or to a biosimilar and its reference product, which treatments could?
Hence, because batches of an original biologic can be deemed to be
interchangeable, biosimilars and their corresponding reference medi-
cines may also be safely reciprocally interchanged, as endorsed by
EMA regulators.14 Indeed, the best scientific claim for interchangeabil-
ity is the demonstration of essential sameness, ie, biosimilarity, based
on a robust comparability programme.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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COMMENTARY 2461Beyond the exhaustive pre‐registration requisites that support
biosimilarity, more than thirteen years of clinical experience have been
amassed while biosimilars have been available on the market, including
extensive switching practice, which has provided overwhelming evi-
dence to sustain the safety of interchanging. Indeed, post‐marketing
clinical studies and real‐world evidence may help physicians more
accurately calibrate the extent of the safety net when facing a
switching decision. The NorSwitch study, fostered by Norwegian
health care authorities, was the first independent, phase IV, random-
ized clinical trial to investigate switching as a primary endpoint.15 The
study confirmed the safety of switching a given patient from being
treated with a reference product containing infliximab to being treated
with a biosimilar version of the medicine. Moreover, a recent meta‐
analysis of more than 90 studies, involving over 14 000 patients, con-
firmed that no specific risks can be attributed to the replacement of a
reference medicine with a biosimilar.16 As highlighted in the meta‐anal-
ysis, immunogenicity is a common matter of concern for prescribers
when making a switching decision. However, the stringent scientific
proof of physicochemical and functional comparability is also key to
substantiating the conclusion of equivalent immunogenicity. Conclu-
sive molecular overlap between biosimilars and reference medicines
is well‐illustrated by the finding that anti‐drug antibodies (ADA)
cross‐react equally with both products.17 Although analytical compara-
bility is reassuring on its own, reference regulatory bodies require case‐
by‐case, pre‐ and post‐authorization immunogenicity‐targeted assess-
ment plans.18 Accordingly, over many years of pharmaceutical surveil-
lance of biosimilar safety and efficacy in European countries, including
switching scenarios in Nordic countries15,19 and more recently in the
United Kingdom,20 no unexpected alerts or warnings have been raised
regarding the development of ADA, or any other adverse effect, as a
result of the presence of biosimilars on the market. Interestingly, the
British Society of Gastroenterology21 recommends to switch to the
biosimilar version patients stabilized, or in remission, with the refer-
ence product containing infliximab. Other learned societies also back
the safety of switching stable patients to biosimilars.22 Although the
scope of this article does not cover this issue, it is worth mentioning
that as new biosimilars for a given reference medicine reach the mar-
ket, interchangeability among biosimilars is also being debated. Given
the stringency of the EMA regulatory framework, patients subject to
any biosimilar‐to‐biosimilar switch are unlikely to face a non‐accept-
able risk. As experience continues to accumulate, registries of patients
who undergo switching may be created to generate supporting evi-
dence, which, in turn, may allow for new clinical guidance to be issued.
Based on the facts reviewed, the demonstration of biosimilarity
under strict regulatory standards, such as the EMA's, parallels the claim
of interchangeability, and interchangeability therefore represents a sci-
entific concept that is inseparable from the biosimilar nature. There-
fore, in contrast to some public positions,23,24 there does not appear
to be any scientific basis for requiring clinical switching studies before
a biosimilar can be granted the designation of “interchangeable.” The
interpretation of such studies would be far less conclusive and reliable
than the data provided by the current totality of the evidence built pri-
marily on the analytical comparability. Indeed, given the degree ofintra‐ and inter‐patient variability in response to treatment, and the
minute molecular differences found among biosimilars and the corre-
sponding reference medicines, trials performed in patients would very
unlikely provide the level of sensitivity required to confidently reflect
the safety of a switching decision. Moreover, requesting such
switching studies would question the foundation of the comparability
model that has been applied successfully for decades to pre‐ and post‐
manufacturing versions of original biopharmaceuticals.
Despite the strength of the science supporting interchangeability,
when two medicines are deemed to be interchangeable, physicians
should be relevant players in any switching decision. The use of
biosimilars should not constitute an exception to this general rule of
the medical practice,particularly because there are several factors
beyond active ingredients that could impact the therapeutic outcome,
such as delivery device‐related issues, or the nocebo effect caused by
a patient's misperception, or expectation, of the treatment. This posi-
tion is advocated by several medical associations, sometimes in a more
cautious manner, like the European Society of Medical Oncology
(ESMO), or the Spanish Society of Rheumatology (SER), that support
interchangeability in stable patients as long as the switch is decided
by the physician in an individualized assessment, and in agreement
with the patient.25,26
An in‐depth understanding of the scientific background supporting
biosimilarity/interchangeability, combined with an appropriate level of
communication with patients, can contribute to the maximization of
the value of biosimilars.27 Their contribution to sustainability and
patient access is the main driver for biosimilars development, and clini-
cians are being increasingly involved in the management of resources
freed up by their use. This has recently been advocated by a decree
issued in France that experimentally encourages biosimilars prescrip-
tion partly based on a redistribution towards the hospital, or the med-
ical department, of the extra budget resulting from an increased
biosimilars utilization.28 Similar initiatives are being progressively gen-
eralized in the United Kingdom.29 Despite the economic grounds that
primarily promote the development of biosimilars, their therapeutic
use should rely on scientific principles. A science‐based understanding
of interchangeability may raise confidence among physicians that cur-
rently prescribe biosimilars only in naïve patients, and may make them
more comfortable switching from the reference medicine to a
biosimilar, to further foster the positive impact of biosimilars.COMPETING INTERESTS
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